Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
Antonio Marra, Sarat Chandarlapaty, Shanu Modi
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 185-202
Closed Access | Times Cited: 43

Showing 26-50 of 43 citing articles:

Targeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibition
Şeyma Demirsoy, Ha Tran, Joseph N. Liu, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2253-2253
Open Access | Times Cited: 1
Role of UFMylation in tumorigenesis and cancer immunotherapy
Lijuan Ding, Xin Jiang, Te Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Predicting Pathological Characteristics of HER2-Positive Breast Cancer from Ultrasound Images: a Deep Ensemble Approach
Zhihui Chen, Hailing Zha, Qing Yao, et al.
Deleted Journal (2024)
Closed Access | Times Cited: 1
Intratumor heterogeneity in breast cancer: Tracing its origins and translating findings into clinical practice
Tian-Qi Gu, Yu-Ling Xiao, Zhi-Ming Shao
Precision medicine and engineering. (2024) Vol. 1, Iss. 1, pp. 100006-100006
Open Access | Times Cited: 1
Subdivision of M1 category and prognostic stage for de novo metastatic breast cancer to enhance prognostic prediction and guide the selection of locoregional therapy
Lei Ji, Ge Song, Min Xiao, et al.
Thoracic Cancer (2024) Vol. 15, Iss. 30, pp. 2193-2205
Open Access | Times Cited: 1
scPharm: Identifying Pharmacological Subpopulations of Single Cells for Precision Medicine in Cancers
Peng Tian, Jie Zheng, Keying Qiao, et al.
Advanced Science (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 1
Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer
Zongbi Yi, Kaixiang Feng, Dan Lv, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 1
Herausforderung Sequenztherapie: Wie neue Substanzen in Therapie einordnen? - Metastasiertes HER2-positives Mammakarzinom
Marika Henriette Princk, Maggie Banys‐Paluchowski
Trillium Krebsmedizin (2024) Vol. 33, Iss. 2, pp. 10-107
Closed Access
Rational design of HER2-targeted combination therapies to reverse drug resistance in fibroblast-protected HER2+ breast cancer cells
Matthew D. Poskus, Jacob D. McDonald, Matthew Laird, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Bridging Discoveries and Treatments: The New Landscape of Breast Cancer Research
Taobo Hu, Lei Wang, Riccardo Autelli, et al.
Life (2024) Vol. 14, Iss. 6, pp. 747-747
Open Access
Tyrosine kinase inhibitors in HER2‐positive metastatic breast cancer with trastuzumab emtansine resistance: insights from a multicenter retrospective real‐world study
Chunxiao Sun, Yijia Hua, Nan Jin, et al.
MedComm (2024) Vol. 5, Iss. 7
Open Access
Biological mechanisms of resistance to trastuzumab and ways to overcome them: Mod-ern problems of clinical oncology
О. І. Vynnychenko, Roman Moskalenko
Regulatory Mechanisms in Biosystems (2024) Vol. 15, Iss. 2, pp. 345-352
Open Access
Coupling of Some Carbazole Analogs with 3pjc Protein Surface as JAK3 Inhibitors
Lauro Figueroa-Valverde, Rosas‐Nexticapa Marcela, Catalina Cervantes-Ortega, et al.
Clinical Cancer Investigation Journal (2024) Vol. 13, Iss. 4, pp. 7-14
Closed Access
Rational Design of HER2-Targeted Combination Therapies to Reverse Drug Resistance in Fibroblast-Protected HER2+ Breast Cancer Cells
Matthew D. Poskus, Jacob D. McDonald, Matthew Laird, et al.
Cellular and Molecular Bioengineering (2024) Vol. 17, Iss. 5, pp. 491-506
Open Access
A Case Report of Neoadjuvant Therapy for HER-2 Over-Expressing Breast Cancer
忆苏 徐
Advances in Clinical Medicine (2024) Vol. 14, Iss. 11, pp. 253-256
Closed Access
Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab resistant HER2 positive breast cancer
Yijia Hua, Ningjun Duan, Chunxiao Sun, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Drug repurposing opportunities for breast cancer and seven common subtypes
Yilong Lin, Songsong Wang, Yun Zhang, et al.
The Journal of Steroid Biochemistry and Molecular Biology (2024) Vol. 246, pp. 106652-106652
Closed Access
Predictive Factors of Antibody–Drug Conjugate Treatment in Metastatic Breast Cancer: A Narrative Review
Gennaro Gadaleta‐Caldarola, Laura Lanotte, Anna Santoro, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 4082-4082
Open Access
Previous Page - Page 2

Scroll to top